口服伊维菌素对比5%氯菊酯乳膏治疗儿童和成人典型疥疮:多中心、评估者盲法、整群随机临床试验
该多中心、评估者盲法、整群随机临床试验在法国28家医院纳入经皮肤镜检查确诊的典型疥疮指示病例及其家庭成员,比较口服伊维菌素与5%氯菊酯乳膏在第0天和第10天给药后第28天的临床治愈率。结果显示,伊维菌素组整群治愈率为71.8%,氯菊酯组为88.5%,差异为-16.7个百分点(95%CI -26.3至-7.1),未显示伊维菌素相对于氯菊酯的非劣效性,反而显示氯菊酯具有统计学优势。
要点
- 在经皮肤镜确诊的典型疥疮指示病例及其家庭成员中,口服伊维菌素组第28天整群临床治愈率为71.8%,低于5%氯菊酯乳膏组的88.5%。
- 指示病例层面治愈率伊维菌素组为76.6%,氯菊酯组为91.5%,差异为-14.9个百分点(95%CI -23.6至-6.2)。
- 参与者层面治愈率伊维菌素组为85.3%,氯菊酯组为94.2%,差异为-9.2个百分点(95%CI -14.9至-3.5)。
核心结论
- 该整群随机试验未显示口服伊维菌素相对于5%氯菊酯乳膏在第0天和第10天给药后第28天实现指示病例及其家庭成员临床治愈方面的非劣效性,反而显示5%氯菊酯乳膏具有统计学优势。
研究设计与样本
- 多中心、评估者盲法、整群随机临床试验,在法国28家医院于2016年1月19日至2021年12月16日开展。
- 纳入经皮肤镜检查确诊的疥疮指示病例(体重>15 kg的成人和儿童),指示病例按1:1比例随机分配至伊维菌素组或氯菊酯组,其家庭成员接受与指示病例相同的治疗,但体重<15 kg的儿童给予外用5%氯菊酯乳膏。
- 伊维菌素组142户家庭(整群)共507名参与者接受治疗,氯菊酯组147户家庭共568名参与者接受治疗。
主要发现
- 第28天整群临床治愈率伊维菌素组为71.8%,氯菊酯组为88.5%,差异为-16.7个百分点(95%CI -26.3至-7.1)。
- 指示病例层面治愈率伊维菌素组为76.6%,氯菊酯组为91.5%,差异为-14.9个百分点(95%CI -23.6至-6.2)。
- 参与者层面治愈率伊维菌素组为85.3%,氯菊酯组为94.2%,差异为-9.2个百分点(95%CI -14.9至-3.5)。
- 所有整群的组内相关系数氯菊酯组为0.68(95%CI 0.61至0.75),伊维菌素组为0.46(95%CI 0.37至0.56);整群大小>1时氯菊酯组为0.67(95%CI 0.60至0.74),伊维菌素组为0.47(95%CI 0.37至0.56)。
- 皮肤不良事件发生率伊维菌素组为11.9%,氯菊酯组为15.6%。
关键数值与推荐
- 主要结局为第28天整群临床治愈,即所有整群成员的疥疮临床体征和症状消失。
- 所有参与者均在第0天和第10天接受口服伊维菌素200 µg/kg或5%氯菊酯乳膏全身涂抹(从头到脚)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether oral ivermectin or topical 5% permethrin can clinically cure scabies in index cases and in members of their households. DESIGN: Multicentre, assessor blinded, cluster randomised clinical trial. SETTING: 28 French hospitals, 19 January 2016 to 16 December 2021. PARTICIPANTS: Index cases; adults and children weighing >15 kg with scabies, confirmed by dermoscopy. INTERVENTIONS: Index cases were randomly assigned to the ivermectin group or permethrin group (1:1 ratio). Each member of the cluster, defined as the household of each index case, received the same treatment as the index case, except for children weighing <15 kg who were prescribed topical 5% permethrin. All participants received oral ivermectin 200 µg/kg or 5% permethrin cream on day 0 and day 10. Permethrin cream was applied to the whole body, from head to toe. MAIN OUTCOME MEASURES: The primary outcome was clinical cure of the cluster on day 28 (ie, disappearance of clinical signs and symptoms of scabies for all cluster members). Secondary outcomes were index case and individual level analyses and safety. Dermatologists were used as assessors and were masked to the treatment. RESULTS: 507 participants in 142 households (clusters) were treated with ivermectin and 568 participants in 147 households received permethrin. Cluster level cure rates were 71.8% versus 88.5% (-16.7 percentage point difference, 95% confidence interval (CI) -26.3 to -7.1) for ivermectin versus permethrin. Secondary outcome percentage point differences also showed the inferiority of ivermectin compared with 5% permethrin for index cases (76.6% v 91.5%; percentage point difference -14.9, 95% CI -23.6 to -6.2) and participants (85.3% v 94.2%; -9.2 percentage point difference, -14.9 to -3.5). Intraclass correlation coefficients were higher for permethrin than ivermectin for all clusters (0.68, 95% CI 0.61 to 0.75 v 0.46, 0.37 to 0.56) and for cluster size >1 (0.67, 0.60 to 0.74 v 0.47, 0.37 to 0.56). Cutaneous adverse events were found in 11.9% and 15.6% of participants treated with ivermectin and permethrin, respectively. CONCLUSIONS: The results of this cluster randomised trial of classic scabies, confirmed by dermoscopy, did not show the non-inferiority of oral ivermectin compared with 5% permethrin cream, given on days 0 and 10, in achieving clinical cure of scabies on day 28 in index cases and their household members. Conversely, the trial showed the statistical superiority of 5% permethrin cream. TRIAL REGISTRATION: NCT02407782.
引用
- Boralevi F, Simon G, Bernigaud C, et al. Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicentre, assessor blinded, cluster randomised clinical trial. BMJ. 2026. PMID: 41494769. doi:10.1136/bmj-2025-086277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。